A detailed history of American Portfolios Advisors transactions in Immuno Gen, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 50 shares of IMGN stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50
Holding current value
$0
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$4.48 - $6.47 $224 - $323
50 New
50 $239,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.